Phaseline

Companies › Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Belzutifan (PT2977)
Endothelial PAS domain-containing protein 1 inhibitor
EPAS1Phase 2Renal Cell Carcinoma (RCC); VHL - Von Hippel-Lindau Syndrome; Advanced Solid Tumors; ccRCCNov 2026
MK-3795
HIF-2α inhibitor
HIF2APhase 1ccRCCNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02974738Belzutifan (PT2977)Phase 1Advanced Solid TumorsOncologyNov 2026
NCT02293980Belzutifan (PT2977)Phase 1ccRCCOncologyNov 2026
NCT02293980MK-3795Phase 1ccRCCOncologyNov 2026
NCT03634540Belzutifan (PT2977)Phase 2Renal Cell Carcinoma (RCC)OncologyFeb 2027
NCT03401788Belzutifan (PT2977)Phase 2VHL - Von Hippel-Lindau SyndromeOncologyApr 2027

Targets

EPAS1 (1) HIF2A (1)

Companies with the same targets

Merck & Co. (MSD) Jiangsu Hansoh Pharmaceutical

Companies built like this

Vividion Therapeutics Neonc Technologies GI Innovation iTeos Therapeutics EpicentRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.